PL3388064T3 - Pochodne 2,4-tiazolidynodionu w leczeniu zaburzeń ośrodkowego układu nerwowego - Google Patents

Pochodne 2,4-tiazolidynodionu w leczeniu zaburzeń ośrodkowego układu nerwowego

Info

Publication number: PL3388064T3
Authority: PL; Poland
Prior art keywords: treatment; nervous system; central nervous; system disorders; thiazolidinedione derivatives
Prior art date: 2014-04-02

Application number

PL18173541T

Other languages

English (en)

Inventor

Ana María GARCÍA COLLAZO

David John Augustus ECKLAND

Maria Pilar Pizcueta Lalanza

Marc Martinell Pedemonte

Original Assignee

Minoryx Therapeutics S.L.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-04-02

Filing date

2015-04-01

Publication date

2021-07-19

2015-04-01 Application filed by Minoryx Therapeutics S.L. filed Critical Minoryx Therapeutics S.L.

2021-07-19 Publication of PL3388064T3 publication Critical patent/PL3388064T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Dispersion Chemistry (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Oncology (AREA)
Cardiology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL18173541T 2014-04-02 2015-04-01 Pochodne 2,4-tiazolidynodionu w leczeniu zaburzeń ośrodkowego układu nerwowego PL3388064T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP14382130		2014-04-02
PCT/EP2015/057224 WO2015150476A1 (en)	2014-04-02	2015-04-01	2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
EP18173541.6A EP3388064B1 (en)	2014-04-02	2015-04-01	2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
EP15713499.0A EP3125888B1 (en)	2014-04-02	2015-04-01	2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders

Publications (1)

Publication Number	Publication Date
PL3388064T3 true PL3388064T3 (pl)	2021-07-19

Family

ID=50513194

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL18173541T PL3388064T3 (pl)	2014-04-02	2015-04-01	Pochodne 2,4-tiazolidynodionu w leczeniu zaburzeń ośrodkowego układu nerwowego
PL15713499T PL3125888T3 (pl)	2014-04-02	2015-04-01	Pochodne 2,4-tiazolidynodionu w leczeniu zaburzeń ośrodkowego układu nerwowego

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL15713499T PL3125888T3 (pl)	2014-04-02	2015-04-01	Pochodne 2,4-tiazolidynodionu w leczeniu zaburzeń ośrodkowego układu nerwowego

Country Status (24)

Country	Link
US (3)	US9782395B2 (pl)
EP (2)	EP3125888B1 (pl)
JP (2)	JP6745726B2 (pl)
KR (1)	KR102418167B1 (pl)
CN (1)	CN106470991B (pl)
AU (1)	AU2015239112C1 (pl)
CA (1)	CA2943373C (pl)
CL (1)	CL2016002508A1 (pl)
CY (2)	CY1120454T1 (pl)
DK (2)	DK3125888T3 (pl)
EA (2)	EA202091120A3 (pl)
ES (2)	ES2872335T3 (pl)
HR (2)	HRP20180983T1 (pl)
HU (2)	HUE039555T2 (pl)
IL (1)	IL248037B (pl)
LT (2)	LT3125888T (pl)
MX (1)	MX373234B (pl)
NZ (1)	NZ725492A (pl)
PL (2)	PL3388064T3 (pl)
PT (2)	PT3388064T (pl)
SG (1)	SG11201608218QA (pl)
SI (2)	SI3125888T1 (pl)
WO (1)	WO2015150476A1 (pl)
ZA (1)	ZA201607286B (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8722710B2 (en)	2007-09-26	2014-05-13	Deuterx, Llc	Deuterium-enriched pioglitazone
US20130158077A1 (en)	2011-12-19	2013-06-20	Ares Trading S.A.	Pharmaceutical compositions
JP6800013B2 (ja)	2013-03-14	2020-12-16	ポクセル・ソシエテ・アノニムＰｏｘｅｌＳＡ	重水素化２，４−チアゾリジンジオン及び治療方法
EP3666273A3 (en)	2014-01-15	2020-10-28	Poxel SA	Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
ES2872335T3 (es) *	2014-04-02	2021-11-02	Minoryx Therapeutics S L	Derivados de 2,4-tiazolidindiona en el tratamiento de trastornos del sistema nervioso central
JP7040798B2 (ja) *	2016-12-01	2022-03-23	ミノリックスセラピューティクスエセ．エレ．	非アルコール性脂肪性肝疾患を処置するための５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオン
MX379709B (es) *	2016-12-23	2025-03-11	Minoryx Therapeutics S L	Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil] etoxi]fenil]metil]-2,4-tiazolidindiona y sus sales.
WO2019234690A1 (en) *	2018-06-06	2019-12-12	Minoryx Therapeutics S.L.	Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts
KR20210031435A (ko)	2018-06-06	2021-03-19	미노릭스 테라퓨틱스 에스.엘.	치료학적 유효량의 5-[[4-[2-[5-(1-히드록시에틸)피리딘-2-일]에톡시]페닐]메틸]-1,3-티아졸리딘-2,4-디온을 투여하는 방법
EP3801515B1 (en) *	2018-06-06	2025-04-09	Minoryx Therapeutics S.L.	5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases
MX2022013021A (es)	2020-04-30	2023-01-16	Minoryx Therapeutics S L	Leriglitazona para tratar inflamacion pulmonar y enfermedad pulmonar intersticial.
US11319313B2 (en)	2020-06-30	2022-05-03	Poxel Sa	Crystalline forms of deuterium-enriched pioglitazone
US11767317B1 (en)	2020-06-30	2023-09-26	Poxel Sa	Methods of synthesizing enantiopure deuterium-enriched pioglitazone
WO2024141951A1 (en)	2022-12-28	2024-07-04	Minoryx Therapeutics S.L.	Optimized dosing of leriglitazone
WO2024231881A2 (en)	2023-05-09	2024-11-14	Minoryx Therapeutics S.L.	Polymorphic forms and formulations of leriglitazone

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5441971A (en)	1991-04-11	1995-08-15	The Upjohn Company	Thiazolidinedione derivatives, production and use thereof
EP0579733B1 (en) *	1991-04-11	2001-06-20	PHARMACIA & UPJOHN COMPANY	Thiazolidinedione derivatives, production and use thereof
AU4104593A (en) *	1992-05-05	1993-11-29	Upjohn Company, The	A process for producing pioglitazone metabolite
US5952509A (en)	1996-06-27	1999-09-14	Takeda Chemical Industries, Ltd.	Production of benzaldehyde compounds
US6191154B1 (en)	1998-11-27	2001-02-20	Case Western Reserve University	Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US6294192B1 (en)	1999-02-26	2001-09-25	Lipocine, Inc.	Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6720001B2 (en)	1999-10-18	2004-04-13	Lipocine, Inc.	Emulsion compositions for polyfunctional active ingredients
WO2003055485A1 (en)	2001-12-21	2003-07-10	Smithkline Beecham Corporation	Dosing regimen for ppar-gamma activators
US8993773B2 (en)	2002-07-16	2015-03-31	Cadila Healthcare Limited	Process to prepare pioglitazone via several novel intermediates
AU2003254146A1 (en) *	2003-07-24	2005-03-07	Case Western Reserve University	Methods for the treatment of parkinson's disease
HUE035314T2 (en)	2006-03-16	2018-05-02	Metabolic Solutions Dev Co Llc	Thiazolidinedione analogues for the treatment of a disease mediated by metabolic inflammation
US8722710B2 (en)	2007-09-26	2014-05-13	Deuterx, Llc	Deuterium-enriched pioglitazone
EP3202401B1 (en) *	2009-12-15	2019-10-23	Cirius Therapeutics, Inc.	Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
US8895536B2 (en)	2010-10-29	2014-11-25	Infirst Healthcare Ltd.	Compositions and methods for treating chronic inflammation and inflammatory diseases
US20150224120A1 (en)	2011-09-14	2015-08-13	Catherine Clelland	Compositions and methods for treating hyperprolinemia-associated mental disorders
US8865747B2 (en) *	2012-03-23	2014-10-21	Fundació Institute D'Investigació Biomėdica de Bellvitge (IDIBELL)	Pioglitazone for use in the treatment of adrenoleukodystrophy
US20140178456A1 (en)	2012-08-30	2014-06-26	Udaya Sankar Devanaboyina	Methods and compositions for treating type 2 diabetes and related conditions
JP6800013B2 (ja)	2013-03-14	2020-12-16	ポクセル・ソシエテ・アノニムＰｏｘｅｌＳＡ	重水素化２，４−チアゾリジンジオン及び治療方法
EP3666273A3 (en)	2014-01-15	2020-10-28	Poxel SA	Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
ES2872335T3 (es) *	2014-04-02	2021-11-02	Minoryx Therapeutics S L	Derivados de 2,4-tiazolidindiona en el tratamiento de trastornos del sistema nervioso central

2015
- 2015-04-01 ES ES18173541T patent/ES2872335T3/es active Active
- 2015-04-01 MX MX2016012687A patent/MX373234B/es active IP Right Grant
- 2015-04-01 KR KR1020167030649A patent/KR102418167B1/ko active Active
- 2015-04-01 DK DK15713499.0T patent/DK3125888T3/en active
- 2015-04-01 SI SI201530325T patent/SI3125888T1/en unknown
- 2015-04-01 DK DK18173541.6T patent/DK3388064T3/da active
- 2015-04-01 PT PT181735416T patent/PT3388064T/pt unknown
- 2015-04-01 SI SI201531591T patent/SI3388064T1/sl unknown
- 2015-04-01 LT LTEP15713499.0T patent/LT3125888T/lt unknown
- 2015-04-01 CN CN201580018404.6A patent/CN106470991B/zh active Active
- 2015-04-01 JP JP2016560727A patent/JP6745726B2/ja active Active
- 2015-04-01 ES ES15713499.0T patent/ES2678046T3/es active Active
- 2015-04-01 SG SG11201608218QA patent/SG11201608218QA/en unknown
- 2015-04-01 HU HUE15713499A patent/HUE039555T2/hu unknown
- 2015-04-01 HU HUE18173541A patent/HUE055351T2/hu unknown
- 2015-04-01 EP EP15713499.0A patent/EP3125888B1/en active Active
- 2015-04-01 EA EA202091120A patent/EA202091120A3/ru unknown
- 2015-04-01 WO PCT/EP2015/057224 patent/WO2015150476A1/en active Application Filing
- 2015-04-01 EA EA201691997A patent/EA035866B1/ru unknown
- 2015-04-01 EP EP18173541.6A patent/EP3388064B1/en active Active
- 2015-04-01 NZ NZ725492A patent/NZ725492A/en unknown
- 2015-04-01 CA CA2943373A patent/CA2943373C/en active Active
- 2015-04-01 PL PL18173541T patent/PL3388064T3/pl unknown
- 2015-04-01 AU AU2015239112A patent/AU2015239112C1/en active Active
- 2015-04-01 LT LTEP18173541.6T patent/LT3388064T/lt unknown
- 2015-04-01 PT PT157134990T patent/PT3125888T/pt unknown
- 2015-04-01 PL PL15713499T patent/PL3125888T3/pl unknown
2016
- 2016-05-05 US US15/147,484 patent/US9782395B2/en active Active
- 2016-09-26 IL IL248037A patent/IL248037B/en active IP Right Grant
- 2016-10-03 CL CL2016002508A patent/CL2016002508A1/es unknown
- 2016-10-21 ZA ZA2016/07286A patent/ZA201607286B/en unknown
2017
- 2017-10-05 US US15/725,950 patent/US10179126B2/en active Active
2018
- 2018-06-26 HR HRP20180983TT patent/HRP20180983T1/hr unknown
- 2018-07-23 CY CY20181100765T patent/CY1120454T1/el unknown
- 2018-12-13 US US16/218,829 patent/US20190255032A1/en not_active Abandoned
2020
- 2020-05-07 JP JP2020081949A patent/JP2020117539A/ja active Pending
2021
- 2021-03-30 HR HRP20210518TT patent/HRP20210518T1/hr unknown
- 2021-04-27 CY CY20211100363T patent/CY1124088T1/el unknown

Also Published As

Publication number	Publication date
US10179126B2 (en)	2019-01-15
EA202091120A3 (ru)	2020-12-30
CN106470991B (zh)	2020-07-31
CA2943373C (en)	2023-01-10
US20160235729A1 (en)	2016-08-18
PL3125888T3 (pl)	2018-09-28
KR102418167B1 (ko)	2022-07-08
LT3388064T (lt)	2021-05-25
IL248037B (en)	2020-09-30
EP3125888A1 (en)	2017-02-08
PT3388064T (pt)	2021-05-14
CA2943373A1 (en)	2015-10-08
LT3125888T (lt)	2018-07-10
MX373234B (es)	2020-05-08
HUE055351T2 (hu)	2022-05-28
JP2020117539A (ja)	2020-08-06
SI3388064T1 (sl)	2021-08-31
EA202091120A2 (ru)	2020-08-31
ES2678046T3 (es)	2018-08-08
HUE039555T2 (hu)	2019-01-28
EA201691997A1 (ru)	2017-02-28
JP6745726B2 (ja)	2020-08-26
AU2015239112C1 (en)	2020-08-20
SI3125888T1 (en)	2018-08-31
EP3125888B1 (en)	2018-05-23
JP2017511339A (ja)	2017-04-20
AU2015239112A1 (en)	2016-11-10
HRP20180983T1 (hr)	2018-08-10
MX2016012687A (es)	2017-04-27
US20190255032A1 (en)	2019-08-22
AU2015239112B2 (en)	2020-05-07
CN106470991A (zh)	2017-03-01
EP3388064B1 (en)	2021-03-10
BR112016022974A2 (pt)	2017-12-26
DK3388064T3 (da)	2021-04-19
EA035866B1 (ru)	2020-08-21
WO2015150476A1 (en)	2015-10-08
CY1124088T1 (el)	2022-05-27
DK3125888T3 (en)	2018-06-25
NZ725492A (en)	2023-06-30
CL2016002508A1 (es)	2017-04-21
PT3125888T (pt)	2018-07-20
ZA201607286B (en)	2021-07-28
IL248037A0 (en)	2016-11-30
HRP20210518T1 (hr)	2021-05-14
EP3388064A1 (en)	2018-10-17
KR20160145639A (ko)	2016-12-20
US9782395B2 (en)	2017-10-10
US20180133202A1 (en)	2018-05-17
SG11201608218QA (en)	2016-10-28
ES2872335T3 (es)	2021-11-02
CY1120454T1 (el)	2019-07-10

Publication	Publication Date	Title
HRP20210518T1 (hr)	2021-05-14	Derivati 2,4-tiazolidindiona, namijenjeni liječenju poremećaja središnjeg živčanog sustava
IL258471A (en)	2018-05-31	11,13-modified saxitoxins for the treatment of pain
IL247841A0 (en)	2016-11-30	Heterocyclic compounds for use in the treatment of disorders mediated by pi3k gamma
IL249502B (en)	2020-09-30	New therapeutic uses of benzylideneguanidine derivatives for the treatment of diseases caused by structurally abnormal proteins
SI3452465T1 (sl)	2021-04-30	Substituirani derivati 2,4-diamino-kinolina za uporabo v zdravljenju proliferativnih bolezni
IL256350A (en)	2018-02-28	Compositions and methods for the treatment of substance use disorders, addiction, and psychiatric disorders
HUE039750T2 (hu)	2019-02-28	Hidroxi-buspiron mozgászavarok kezelésére
HRP20220490T8 (hr)	2022-06-10	Spojevi tiazolidinona i njihova upotreba u liječenju psihijatrijskih ili neuroloških poremećaja i inflamacije, posebno neuroinflamacije
HRP20181123T1 (hr)	2018-09-21	Spojevi 3,4-diamino-6-kloropirazin-2-karboksamida za liječenje bolesti posredovanih s enac
EP3507277B8 (en)	2021-03-03	Hydroxynorketamine derivatives for the treatment of disorders
DK3148588T3 (en)	2021-07-26	N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease
PT3148990T (pt)	2022-05-02	Compostos de tiazolidinona e seu uso no tratamento de condições psiquiátricas ou distúrbios neurológicos e inflamação, particularmente neuroinflamação
TH1601002629A (th)	2017-08-10	ไพริโด[4,3-b]ไพราซีน-2-คาร์บอกซาไมด์ ในรูปสารก่อกำเนิดประสาทสำหรับ การรักษาความผิดปกติที่มีภาวะเสื่อมของระบบประสาท
GB201602011D0 (en)	2016-03-23	Treating skin disorders
GB201413533D0 (en)	2014-09-10	Combination therapy for treating disorders of the vestibular system
GB201416044D0 (en)	2014-10-22	The way, Mental Health Therapeutic Technique